MetaCap

Spero Therapeutics (SPRO) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Spero Therapeutics (SPRO) over the past year, losing 41.4% versus a loss of 67.9%. Over five years, TLPH leads with a -94.0% price change compared with -95.1% for SPRO. Spero Therapeutics is the larger company by market cap ($43.2 million vs $40.8 million), about 1.1 times the size.

Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -51035.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SPRO-67.88%TLPH-41.40%
+34%-19%-73%
Nov 21, 20251 yearNov 20, 2026
SPRO-95.50%TLPH-94.55%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SPRO versus TLPH key metrics
MetricSPROTLPH
Share price$0.742$0.7852
Market cap$43.23M$40.80M
1-day change-10.20%+6.25%
YTD return-68.15%-31.12%
1-year return-67.88%-41.40%
5-year return-95.09%-93.96%
EPS (TTM)$-0.50$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$66.80M$28.00K
Revenue growth (YoY)+39.24%—
Net income (latest FY)$8.57M$-14.29M
Operating margin9.45%-48157.14%
Net margin12.83%-51035.71%
52-week high$3.08$1.57
52-week low$0.73$0.69
Distance from 52-week high-75.91%-49.99%
Analyst consensusnonenone
Avg. price target upside+573.85%+298.62%
Average volume530.46K144.13K
Shares outstanding58.26M51.96M
Employees2512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed SPRO by 26.5 percentage points over the past year.
  • Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -51035.7 cents for Talphera.

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

SPRO vs TLPH FAQ

Which is bigger, Spero Therapeutics or Talphera?

Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $40.80M for Talphera (TLPH).

Which stock has performed better over the past year, SPRO or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.

Are Spero Therapeutics and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons